<SEC-DOCUMENT>0001552781-16-001946.txt : 20160912
<SEC-HEADER>0001552781-16-001946.hdr.sgml : 20160912
<ACCEPTANCE-DATETIME>20160912171516
ACCESSION NUMBER:		0001552781-16-001946
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160909
ITEM INFORMATION:		Termination of a Material Definitive Agreement
FILED AS OF DATE:		20160912
DATE AS OF CHANGE:		20160912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		161881543

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e00496_mgnx-8k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>WASHINGTON, D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">____________________</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of report (Date of earliest event reported):&nbsp;
<B>September 9, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MACROGENICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><BR>
(Exact Name of Registrant as Specified in Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 30%; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-36112</B></FONT></TD>
    <TD STYLE="width: 34%; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><B>06-1591613</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or Other Jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of Incorporation)</P></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(Commission</FONT><BR>
<FONT STYLE="font-size: 10pt">File Number)</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 66%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>9704 Medical Center Drive, </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Rockville, Maryland</B></P></TD>
    <TD STYLE="width: 34%; font: 12pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>20850</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant's telephone number, including area
code:&nbsp; <B>(301) 251-5172</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Not applicable&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#9744; Written communications pursuant to
Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#9744; Soliciting material pursuant to Rule&nbsp;14a-12
under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#9744; Pre-commencement communications pursuant
to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#9744; Pre-commencement communications pursuant
to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Silver 1pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item&nbsp;1.02 Termination of a Material Definitive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">MacroGenics, Inc. (the &ldquo;Company&rdquo;)
and Takeda Pharmaceutical Company Limited (&ldquo;Takeda&rdquo;) are parties to a license and option agreement (the &ldquo;Agreement&rdquo;)
relating to the development and commercialization of MGD010, currently in Phase 1a of clinical development for the treatment of
autoimmune diseases. The Agreement included an option for Takeda to obtain an exclusive worldwide license for MGD010 following
the completion of the pre-defined Phase 1a study. On September 9, 2016, prior to the predefined expiration of Takeda&rsquo;s option
exercise period and following its recently announced therapeutic area re-prioritization, Takeda provided written notice to the
Company declining the option and terminating the Agreement. If Takeda had exercised the option, it would have assumed responsibility
for future development and paid the Company an option exercise fee. Upon termination of the Agreement, the Company regains the
worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company and Takeda are also parties
to a separate research collaboration that was entered into in September 2014 and is unaffected by termination of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing description of the Agreement
is qualified in its entirety by the terms of the Agreement, which the Company filed as an exhibit to its Quarterly Report on Form
10-Q for the three months ended June 30, 2014. Additionally, on September 12, 2016, the Company issued a press release announcing
the termination of the Agreement, a copy of which is filed as Exhibit 99.1 to this Current Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 100%; color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:&nbsp; September 12, 2016</FONT></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MACROGENICS, INC.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Atul Saran&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Atul Saran</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Sr. VP and General Counsel</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Silver 1pt solid"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>e00496_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 17pt Georgia, Times, Serif; margin: 0; color: black">Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; color: black">MacroGenics regains worldwide rights to DART molecule for
autoimmune disorders</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">Rockville, MD, Sept. 12, 2016 (GLOBE NEWSWIRE) -- and Osaka,
Japan, Sept. 12, 2016 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and
developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced the conclusion of their License and Option Agreement
for MGD010. MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda&rsquo;s
decision comes earlier than the predefined expiration of its option exercise period and follows Takeda&rsquo;s recently announced
therapeutic area re-prioritization. Takeda&rsquo;s decision was not based on the ongoing Phase 1 study with MGD010. MacroGenics
plans to continue to advance the development of this product candidate based on the positive study results reported to date.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">&ldquo;We presented promising interim data from our ongoing
Phase 1 study of MGD010 in an oral presentation at the Annual European Congress of Rheumatology (EULAR 2016) in London this past
June,&rdquo; said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. &ldquo;We view Takeda&rsquo;s early decision to not
exercise its option as an opportunity for MacroGenics. This enables us to further develop MGD010 on our own or explore future strategic
partnering opportunities with this program.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">&ldquo;We have enjoyed collaborating with MacroGenics on this
development project,&rdquo; said Takeda&rsquo;s Emiliangelo Ratti, Global Head Central Nervous System Therapeutic Area Unit. &ldquo;While
our re-prioritization on key therapeutic areas has resulted in a change of direction for Takeda&rsquo;s role in this program, we
look forward to MacroGenics&rsquo; continued progress with MGD010 as a potential new therapy for patients suffering from B- cell
mediated autoimmune and inflammatory disorders.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">In May 2014, MacroGenics entered into an agreement with Takeda
regarding MGD010. Under the terms of that agreement, Takeda received an option to obtain an exclusive worldwide license for MGD010
following the delivery of a data package, including data from a completed, pre-defined Phase 1 study. Takeda has given formal notification
it does not intend to exercise this option, allowing MacroGenics to control worldwide development and commercialization rights
to MGD010. To date, MacroGenics has led all MGD010 product development activities. Takeda and MacroGenics are also parties to a
separate research collaboration that was entered into in September 2014.</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">About MGD010</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">MGD010 is a humanized DART molecule that simultaneously targets
CD32B and CD79B. CD32B is a checkpoint molecule expressed on B lymphocytes that, when co-ligated with CD79B, a component of the
B- cell antigen receptor complex, delivers a co-inhibitory signal that dampens B-cell activation. In normal conditions, B cells
utilize CD32B as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disorders do
not occur. MGD010 exploits this mechanism and triggers this inhibitory &ldquo;immune checkpoint&rdquo; loop for the inhibition of
B-cell function, an approach that may be useful for the treatment of patients with autoimmune disorders. In pre-clinical studies,
MGD010 was shown to modulate the function of human B cells without B-cell depletion in a variety of in vitro and in vivo models.
MacroGenics believes this molecule can block those B cells that are activated to produce the pathogenic antibodies and promote
the autoimmune process.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">Interim data from a first-in-human, double-blind, placebo-controlled
Phase 1 study in which a single dose of MGD010 is intravenously (IV) administered to healthy subjects were presented at EULAR 2016.
Initial data from the first 49 subjects showed that MGD010 was well tolerated at all dose levels and no serious adverse effects
were reported. In addition, MGD010 demonstrated linear pharmacokinetics and dose-dependent selective binding to B lymphocytes without
persistent B-cell depletion. The data also showed: (1) a dose- dependent downregulation of B-cell receptor-induced signaling together
with down-modulation of B-cell receptor expression among circulating memory and na&iuml;ve B cells, (2) a decrease in expression
of the costimulatory CD40 molecule and (3) a decrease in circulating immunoglobulin M levels, each consistent with the targeted
action of MGD010. MacroGenics is currently completing the enrollment of an additional 24 healthy subjects in a final segment of
the Phase 1 study, in which subjects will be assessed for immune modulation by MGD010 following Hepatitis A vaccination.</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Silver 1pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">About MacroGenics, Inc.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">MacroGenics is a clinical-stage biopharmaceutical company
focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as
autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates primarily from its proprietary
suite of next-generation antibody-based technology platforms. The combination of MacroGenics&rsquo; technology platforms and protein
engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations
with global pharmaceutical and biotechnology companies. For more information, please see the company&rsquo;s website at www.macrogenics.com.
MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc.</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">MacroGenics&rsquo; Cautionary Note on Forward-Looking
Statements</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">Any statements in this press release about future expectations,
plans and prospects for MacroGenics, including statements about MacroGenics&rsquo; strategy, future operations, clinical development
of its therapeutic candidates, milestone or opt-in payments from MacroGenics&rsquo; collaborators, MacroGenics&rsquo; anticipated
milestones and future expectations and plans and prospects for MacroGenics and other statements containing the words &ldquo;subject
to&rdquo;, &ldquo;believe&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;plan&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;project&rdquo;, &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;should&rdquo;, &ldquo;would&rdquo;, &ldquo;could&rdquo;, &ldquo;can&rdquo;,
the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual
results may differ materially from those indicated by such forward-looking statements as a result of various important factors,
including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing
clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters
that could affect the availability or commercial potential of MacroGenics&rsquo; product candidates and other risks described in
MacroGenics&rsquo; filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in
this press release represent MacroGenics&rsquo; views only as of the date hereof. MacroGenics anticipates that subsequent events
and developments will cause MacroGenics&rsquo; views to change. However, while MacroGenics may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law. These
forward-looking statements should not be relied upon as representing MacroGenics&rsquo; views as of any date subsequent to the
date hereof.</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">About Takeda</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">Takeda Pharmaceutical Company Limited is a global, research
and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&amp;D efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&amp;D both internally and with partners to stay at the leading edge of innovation.
New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth
of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners
in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.</P>

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Silver 1pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">Takeda&rsquo;s Forward-Looking Statements</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">This press release contains &ldquo;forward-looking statements.&rdquo;
Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations
for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing
of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future
revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense,
and words such as &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;continue,&rdquo; &ldquo;believe,&rdquo;
&ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;pro forma,&rdquo; &ldquo;intend,&rdquo; &ldquo;potential,&rdquo; &ldquo;target,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;guidance,&rdquo; &ldquo;outlook,&rdquo; &ldquo;seek,&rdquo; &ldquo;assume,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; and similar expressions are intended to qualify as forward-looking statements. Forward-looking
statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently
uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking
statements.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">Forward-looking statements involve risks and uncertainties
that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.
Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not
be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures
and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory
authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed
products or product candidates in development.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 12pt">The forward-looking statements contained in this press release
speak only as of the date of this press release, and neither MacroGenics nor Takeda undertake any obligation to revise or update
any forward- looking statements to reflect new information, future events or circumstances after the date of the forward- looking
statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional
updates or corrections will be made.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">###</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">MacroGenics &ndash;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Jim Karrels, Senior Vice President, CFO</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">MacroGenics, Inc.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">1-301-251-5172, info@macrogenics.com</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Karen Sharma, Vice President</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">MacDougall Biomedical Communications</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">1-781-235-3060, ksharma@macbiocom.com</P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Takeda Pharmaceutical Company Limited &ndash;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Tsuyoshi Tada &ndash; Japan</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">tsuyoshi.tada@takeda.com</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">+81 332 782 417</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Sandra MacTavish &ndash; U.S.A.</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">sandra.mactavish@takeda.com</P>
        <P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">+1.224.554.2343</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Silver 1pt solid"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
